Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Price Target
View:
Post by scarlet1967 on Jan 20, 2021 8:56am

Price Target

" Theratechnologies : National Bank of Canada resumes coverage with C$3.75 PT"
Also investors presentation is up.
Comment by scarlet1967 on Jan 20, 2021 9:24am
I am not sure these were there in the last IP. Page 21: "Key Differentiators Underpinning Regulatory and Commercial Viability   First-in-class MOA with an upstream approach to underlying causes of NASH De-risked, late-stage clinical program with demonstrated proof-of-concept Statistically significant results in a harder-to-treat patient population, driving optimism for efficacy in a ...more  
Comment by Greenviolino on Jan 20, 2021 10:18am
Analysts have always been behind the curve with TH. I remember buying this stock at 0.30-0.40 when the Mackie analyst had a hold with a 0.60 or 0.70 target. He would then simply move up his price target as the stock went up. As far as I'm concerned, the current analysts following TH have zero credibility. Notwithstanding the current noise, this company is in much better shape than it's ...more  
Comment by scarlet1967 on Jan 20, 2021 10:43am
The analysts covering the company are either incompetent or not Intrested. They also have limited amount of clients vs thousands of retail investors out there. As per Leah "there is no room for failure anymore", so they have accepted they have failed! Questions are what are they going to do about it? what they have learned from pass mistakes and how would they adjust their strategies ...more  
Comment by Bucknelly21 on Jan 20, 2021 10:46am
I believe Phillip is the main problem there.... nice man but he's been the one failing at selling the story for years, now they have something and still can't.
Comment by jeffm34 on Jan 20, 2021 10:55am
Agree totally! 
Comment by scarlet1967 on Jan 20, 2021 12:57pm
The CFO doesn't have the skills to sell and it seems like he is not that competent as a CFO either so he should not be presenting company again. Paul should take over that roll until the IR lady get her act together. Inventive which many have considered as a suitable comps is near all time high with a market cap over $700 k vs THTX's less than $200 k so darn right "there is no room ...more  
Comment by scarlet1967 on Jan 20, 2021 1:10pm
Actually after the recent sell off THTX's valuation is about $170 k.
Comment by scarlet1967 on Jan 20, 2021 1:31pm
Maybe THTX should start talking to French Banks. Cash Position As of September 30, 2020, Inventiva’s cash and cash equivalents stood at €124.6 million, compared to €52.2 million as of June 30, 2020 and €35.8 million as of December 31, 2019. Inventiva’s net cash flow amounted to €88.8 million (net of (€2.4) million exchange rate effect) for the nine months ended September 30, 2020, compared ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities